These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37553297)

  • 61. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.
    Alexander TB; Lacayo NJ; Choi JK; Ribeiro RC; Pui CH; Rubnitz JE
    J Clin Oncol; 2016 Dec; 34(34):4094-4101. PubMed ID: 27507877
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Burke MJ; Ziegler DS; Bautista F; Attarbaschi A; Gore L; Locatelli F; M O'Brien M; Pauly M; Kormany WN; Tian S; Morris CL; Baruchel A
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29999. PubMed ID: 36215217
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
    Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
    Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.
    Shulman DS; Merriam P; Choy E; Guenther LM; Cavanaugh KL; Kao PC; Posner A; Bhushan K; Fairchild G; Barker E; Klega K; Stegmaier K; Crompton BD; London WB; DuBois SG
    Cancer Med; 2023 Jul; 12(14):15207-15216. PubMed ID: 37306107
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Daver N; Boumber Y; Kantarjian H; Ravandi F; Cortes J; Rytting ME; Kawedia JD; Basnett J; Culotta KS; Zeng Z; Lu H; Richie MA; Garris R; Xiao L; Liu W; Baggerly KA; Jabbour E; O'Brien S; Burger J; Bendall LJ; Thomas D; Konopleva M
    Clin Cancer Res; 2015 Jun; 21(12):2704-14. PubMed ID: 25724525
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
    Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
    J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Wayne AS; Huynh V; Hijiya N; Rouce RH; Brown PA; Krueger J; Kitko CL; Ziga ED; Hermiston ML; Richards MK; Baruchel A; Schuberth PC; Rossi J; Zhou L; Goyal L; Jain R; Vezan R; Masouleh BK; Lee DW
    Haematologica; 2023 Mar; 108(3):747-760. PubMed ID: 36263840
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
    J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
    Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
    Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A
    Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.
    Weiss MA; Drullinsky P; Maslak P; Scheinberg D; Golde DW
    Leukemia; 1998 Jun; 12(6):865-8. PubMed ID: 9639412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.